Prokidney Corp Stock Today
| PROK Stock | USD 0.97 0.07 6.73% |
PerformanceVery Weak
| Odds Of DistressAverage
|
ProKidney Corp is selling for 0.97 as of the 19th of March 2025. This is a 6.73% down since the beginning of the trading day. The stock's last reported lowest price was 0.95. ProKidney Corp has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of July 2022 | Category Healthcare | Classification Health Care |
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Prokidney Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 127.97 M outstanding shares of which 11.75 M shares are at this time shorted by private and institutional investors with about 32.91 trading days to cover. More on ProKidney Corp
Moving together with ProKidney Stock
| 0.71 | A | Agilent Technologies | PairCorr |
| 0.88 | ME | 23Andme Holding | PairCorr |
| 0.89 | VANI | Vivani Medical Earnings Call This Week | PairCorr |
Moving against ProKidney Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ProKidney Stock Highlights
| CEO Director | Bruce MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ProKidney Corp can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ProKidney Corp's financial leverage. It provides some insight into what part of ProKidney Corp's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ProKidney Corp (PROK) is traded on NASDAQ Exchange in USA. It is located in 2000 Frontis Plaza Blvd., Winston-Salem, NC, United States, 27103 and employs 163 people. ProKidney Corp is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.81 B. ProKidney Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 127.97 M outstanding shares of which 11.75 M shares are at this time shorted by private and institutional investors with about 32.91 trading days to cover.
ProKidney Corp currently holds about 21.88 M in cash with (126.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36.
Check ProKidney Corp Probability Of Bankruptcy
Ownership AllocationProKidney Corp owns a total of 127.97 Million outstanding shares. ProKidney Corp has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check ProKidney Ownership Details
ProKidney Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-12-31 | 539.2 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 292 K | |
| Nuveen Asset Management, Llc | 2024-12-31 | 266.4 K | |
| Ubs Group Ag | 2024-12-31 | 258.2 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 229.8 K | |
| Barclays Plc | 2024-12-31 | 171.8 K | |
| Amundi | 2024-12-31 | 156 K | |
| Renaissance Technologies Corp | 2024-12-31 | 105.2 K | |
| Alps Advisors Inc | 2024-12-31 | 103.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 14 M | |
| Suvretta Capital Management, Llc | 2024-12-31 | 12.3 M |
ProKidney Corp Historical Income Statement
ProKidney Stock Against Markets
ProKidney Corp Corporate Management
| Ulrich Ernst | EVP Technology | Profile | |
| Joseph MD | VP Devel | Profile | |
| Ashley Johns | VP Operations | Profile | |
| Carla Poulson | Chief Officer | Profile | |
| Lucio Tozzi | Senior Operations | Profile | |
| James CPA | Chief Officer | Profile | |
| Richard Williams | Senior Technology | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProKidney Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.